E-MAIL UPDATES

Click here to join
our Electronic Communications.

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Expands Part C of TACTI-002 due to Positive Data

January 8th 2020
press releases

INSIGHT-004 Clinical Trial Update

December 18th 2019
press releases

Immutep Announces European Patent Grant for LAG525 Antibody

November 13th 2019
press releases
more

Investor updates

Investor updates.

Investor Update - November 2019

November 22nd 2019
investor updates

Investor Update - January 2019

January 31st 2019
investor updates

Investor Update - June 2018

June 19th 2018
investor updates
more

Analyst reports

Analyst reports.

Maxim - TACTI-002 Head & Neck Cancer Study is Expanding, Data Updates Over 2020 – Reiterate Buy

January 10th 2020
analyst reports

Maxim - Runway Through CY20, Upcoming Catalysts ShouldContinue to Drive a Higher Valuation

October 28th 2019
analyst reports

goetzpartners securities - TACTI-mel final data confirm efficacy signals

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

October 15th 2019
analyst reports
more